Pipes Feed Preview: ClinicalTrials.gov: COVID-19 | Last update posted in the last 14 days

1. A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Renal Impairment and in Healthy Subjects with Normal Renal Function

   Thu, 21 Nov 2024 05:00:00 -0000

   Conditions: COVID 19
   Interventions: Drug: ALG-097558
   Sponsors: Aligos Therapeutics; National Institute of Allergy and Infectious Diseases (NIAID)
   Not yet recruiting

2. Boosting COVID-19 Vaccination Uptake Using Wastewater Surveillance

   Thu, 21 Nov 2024 05:00:00 -0000

   Conditions: Vaccine Uptake
   Interventions: Behavioral: Communication Campaign
   Sponsors: Syracuse University
   Active, not recruiting

3. Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older

   Tue, 19 Nov 2024 05:00:00 -0000

   Conditions: COVID-19 Immunization; Influenza Immunization
   Interventions: Biological: RIV (recombinant influenza vaccine); Biological: rC19 (dose 1); Biological: RIV + rC19 (dose 1); Biological: RIV + rC19 (dose 2); Biological: RIV + rC19 (dose 3); Biological: RIV + rC19 (dose 4); Other: Placebo (0.9% NaCl)
   Sponsors: Sanofi
   Not yet recruiting

4. Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

   Tue, 19 Nov 2024 05:00:00 -0000

   Conditions: COVID-19; Influenza
   Interventions: Biological: mRNA-1083; Other: Placebo; Biological: Licensed Influenza Vaccine; Biological: SARS-CoV-2 Vaccine
   Sponsors: ModernaTX, Inc.
   Not yet recruiting

5. Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

   Tue, 19 Nov 2024 05:00:00 -0000

   Conditions: COVID-19 Immunization; Influenza Immunization
   Interventions: Biological: IIV-HD; Biological: rC19 (dose 1); Biological: IIV-HD + rC19 (dose 1); Biological: IIV-HD + rC19 (dose 2); Biological: IIV-HD + rC19 (dose 3); Biological: IIV-HD + rC19 (dose 4); Other: Placebo (0.9% NaCl)
   Sponsors: Sanofi
   Not yet recruiting

6. Predictive Model for High-Flow Nasal Cannula Failure in COVID-19-related Acute Hypoxemic Respiratory Failure Based on Metabolomics and Clinical Data

   Tue, 19 Nov 2024 05:00:00 -0000

   Conditions: Acute Hypoxemic Respiratory Failure; COVID 19
   Sponsors: Hospital del Mar Research Institute (IMIM); Fundacio La Marató de TV3; Instituto de Salud Carlos III; European Union
   Completed

7. Opinions of NKU Faculty of Medicine Interns and Intern Doctors on Distance Medicine Education During the Covid-19 Pandemic Period

   Tue, 19 Nov 2024 05:00:00 -0000

   Conditions: Qualitative Research
   Interventions: Other: survey study
   Sponsors: Namik Kemal University
   Enrolling by invitation

8. Thromboembolic Complications in Mild Covid-19 Cases

   Tue, 19 Nov 2024 05:00:00 -0000

   Conditions: COVID 19; Thromboembolic and Bleeding Complications; Thromboembolism, Venous; Post COVID-19
   Sponsors: Marmara University Pendik Training and Research Hospital
   Completed

9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses

   Mon, 18 Nov 2024 05:00:00 -0000

   Conditions: Severe Viral Pneumonia(Not Include COVID-19)
   Interventions: Drug: Placebo; Drug: Drug therapy; Other: Standard Treatment
   Sponsors: Ruijin Hospital; Ruijin Hospital Affiliated to Shanghai Jiao Tong University; Shulan (Hangzhou) Hospital; Shulan(Quzhou) Hospital; West China Hospital Affiliated with Sichuan University; Zhejiang University; The First Affiliated Hospital of Guangzhou Medical University; Shanghai Zhongshan Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Henan Provincial People's Hospital; Zhongnan Hospital Affiliated to Wuhan University; The First Affiliated Hospital of Nanchang University
   Not yet recruiting

10. A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults

    Mon, 18 Nov 2024 05:00:00 -0000

    Conditions: SARS-CoV-2 Infections
    Interventions: Drug: Treatment B; Drug: Treatment A
    Sponsors: Pfizer
    Not yet recruiting

11. Remote Social Support on Midwifery Students' Anxiety and Attitudes During Distance Education

    Fri, 15 Nov 2024 05:00:00 -0000

    Conditions: Anxiety
    Interventions: Other: Social support
    Sponsors: Istanbul University - Cerrahpasa (IUC)
    Completed

12. Post Authorization Safety Profile of Booster IndoVac COVID-19 Vaccination

    Fri, 15 Nov 2024 05:00:00 -0000

    Conditions: COVID-19
    Sponsors: PT Bio Farma
    Completed

13. Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay

    Thu, 14 Nov 2024 05:00:00 -0000

    Conditions: SARS-CoV-2; COVID-19; RSV; Influenza
    Interventions: Device: Credo POCT Device
    Sponsors: Credo Diagnostics Biomedical Pte. Ltd.; Medical College of Wisconsin
    Not yet recruiting

14. Effect of Non-Invasive Neuromodulation on Primary Chronic Pain, Including Post-COVID-19

    Thu, 14 Nov 2024 05:00:00 -0000

    Conditions: Post COVID Condition; Chronic Pain; Healthy
    Interventions: Device: taVNS - transauricular vagal nerve stimulation; Device: rPMS - repetitive peripheric magnetic stimulation; Device: rTMS - repetitive transcranial magnetic stimulation; Device: taVNS sham
    Sponsors: Federal University of ABC; University of Sao Paulo; Coordination for the Improvement of Higher Education Personnel
    Enrolling by invitation

15. Nordic Walking on Knee Osteoarthritis

    Tue, 12 Nov 2024 05:00:00 -0000

    Conditions: Osteoarthritis of Knee
    Interventions: Other: Nordic walking program; Other: Educational advise
    Sponsors: Consorci Hospitalari de Vic
    Completed

16. Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Prevention of COVID-19-Associated Cytokine Storm

    Thu, 14 Nov 2024 05:00:00 -0000

    Conditions: SARS-CoV-2
    Interventions: Drug: Placebo comparator; Drug: PRS CK STORM; Drug: PRS CK STORM
    Sponsors: PEACHES BIOTECH
    Recruiting

17. Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients with Covid-19. a G2i Study, National Multicenter Observational and Retrospective from June 2023 to April 2024

    Tue, 12 Nov 2024 05:00:00 -0000

    Conditions: Immunocompromised Patients; SARS-CoV-2 Disease
    Interventions: Other: Collection of data from the patient's medical file
    Sponsors: Assistance Publique - Hôpitaux de Paris
    Not yet recruiting

18. A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

    Tue, 12 Nov 2024 05:00:00 -0000

    Conditions: Influenza,Human; COVID-19
    Interventions: Biological: Investigational Influenza Vaccine; Biological: COVID-19 Vaccine; Combination Product: Influenza and COVID Combination Vaccine; Biological: Licensed Influenza Vaccine 1; Biological: Licensed Influenza Vaccine 2; Other: Placebo
    Sponsors: BioNTech SE; Pfizer
    Not yet recruiting

19. A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

    Fri, 15 Nov 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Combination Product: Flu Seasonal /SARS-CoV-2 mRNA Dose 1; Combination Product: Flu Seasonal /SARS-CoV-2 mRNA Dose 2; Combination Product: Flu Seasonal mRNA; Combination Product: SARS-CoV-2 mRNA Dose 1; Combination Product: SARS-CoV-2 mRNA Dose 2; Combination Product: Licensed Flu Seasonal; Combination Product: Licensed COVID-19 mRNA; Drug: Placebo; Combination Product: Phase 2 selected Investigational Flu Seasonal/SARS-CoV-2 mRNA; Combination Product: Phase 2 selected SARS-CoV-2 mRNA
    Sponsors: GlaxoSmithKline
    Recruiting

20. A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

    Thu, 21 Nov 2024 05:00:00 -0000

    Conditions: Coronavirus Disease (COVID-19)
    Interventions: Drug: Molnupiravir; Drug: Placebo
    Sponsors: Merck Sharp & Dohme LLC
    Not yet recruiting

21. Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate

    Tue, 12 Nov 2024 05:00:00 -0000

    Conditions: COVID-19 Immunisation; Influenza Vaccine
    Interventions: Behavioral: Patient letter and clinician communication
    Sponsors: Mayo Clinic; ModernaTX, Inc.
    Recruiting

22. Acupuncture for Post COVID-19 Condition (Long COVID) Neuropsychiatric Symptoms

    Wed, 13 Nov 2024 05:00:00 -0000

    Conditions: Long Covid19; Neuropsychiatric Symptom; Acupuncture
    Interventions: Device: Acupuncture
    Sponsors: Hong Kong Baptist University
    Recruiting

23. Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)

    Thu, 14 Nov 2024 05:00:00 -0000

    Conditions: COVID-19 Vaccination
    Interventions: Biological: Bretovameran
    Sponsors: Pfizer
    Active, not recruiting

24. The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated with the Post-acute Phase of the Infection by Covid-19

    Mon, 18 Nov 2024 05:00:00 -0000

    Conditions: Pulmonary Complications; Cardiovascular Complications; Renal Complications; COVID-19
    Interventions: Other: Blood samples; Other: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
    Sponsors: Hellenic Institute for the Study of Sepsis
    Not yet recruiting

25. A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

    Wed, 20 Nov 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: PF-07817883
    Sponsors: Pfizer
    Recruiting

26. COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

    Fri, 22 Nov 2024 05:00:00 -0000

    Conditions: COVID 19; Influenza; Rheumatoid Arthritis (RA); Systemic Lupus Erthematosus; Inflammatory Bowel Disease; Solid Organ Transplant Recipients; Immunocompromised Host; People Living With HIV
    Interventions: Biological: Inactivated influenza vaccine (IIV) at baseline; Biological: COVID-19 Vaccines at a 3-month interval; Biological: Inactivated influenza vaccine at Month 1; Biological: COVID-19 Vaccines at a 6-month interval
    Sponsors: McGill University Health Centre/Research Institute of the McGill University Health Centre
    Recruiting

27. Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.

    Mon, 18 Nov 2024 05:00:00 -0000

    Conditions: Pneumonia, Community-Acquired; COVID-19 Pneumonia; Cardiovascular Diseases
    Interventions: Other: Blood samples and Oropharyngeal swab; Other: Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
    Sponsors: Hellenic Institute for the Study of Sepsis
    Recruiting

28. Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

    Thu, 21 Nov 2024 05:00:00 -0000

    Conditions: PASC Post Acute Sequelae of COVID-19
    Sponsors: National Institute of Neurological Disorders and Stroke (NINDS)
    Not yet recruiting

29. The Measurement of Chemicals in Exhaled Breath Can Identify If a Person is Infected with COVID-19

    Wed, 20 Nov 2024 05:00:00 -0000

    Conditions: COVID-19
    Sponsors: N5 Sensors; Providence Health & Services; U.S. Department of Homeland Security
    Recruiting

30. COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists: A Stepped-Wedge Trial

    Fri, 22 Nov 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Behavioral: Standard implementation webinar and online training; Behavioral: Virtual facilitation
    Sponsors: University of North Carolina, Chapel Hill; University of Arkansas; University of South Carolina; National Institute on Minority Health and Health Disparities (NIMHD)
    Enrolling by invitation

31. A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants

    Tue, 19 Nov 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: VYD2311; Other: Placebo
    Sponsors: Invivyd, Inc.; Novotech (Australia) Pty Limited
    Active, not recruiting

32. Online Aerobic Exercise and Quality of Life in Non-diagnosed COVID-19 Adults

    Wed, 20 Nov 2024 05:00:00 -0000

    Conditions: Exercise
    Interventions: Other: Online aerobic exercise
    Sponsors: Muş Alparlan University
    Completed

33. RECOVER-SLEEP: Platform Protocol

    Wed, 13 Nov 2024 05:00:00 -0000

    Conditions: Long COVID; Long COVID-19; Hypersomnia; Sleep Disturbance
    Interventions: Drug: Modafinil; Drug: Modafinil Placebo; Drug: Solriamfetol; Drug: Solriamfetol Placebo; Drug: Melatonin; Drug: Melantonin Placebo; Device: Tailored lighting (TL) Active; Device: Tailored lighting (TL) Placebo
    Sponsors: Duke University
    Recruiting

34. A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol

    Thu, 21 Nov 2024 05:00:00 -0000

    Conditions: COVID-19 Infection
    Interventions: Biological: ChAd-triCoV/Mac; Other: Control
    Sponsors: McMaster University; Canadian Institutes of Health Research (CIHR)
    Not yet recruiting

35. A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients

    Tue, 12 Nov 2024 05:00:00 -0000

    Conditions: COVID 19 Associated Coagulopathy
    Interventions: Drug: Troxerutin; Drug: Placebo; Drug: placebo + low molecular weight heparin; Drug: troxerutin + low molecular weight heparin
    Sponsors: Westlake University; Shaoxing Central Hospital; Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
    Recruiting

36. Fascial Tissue Response to Manual Therapy: Implications in Long COVID-19

    Wed, 20 Nov 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Other: Guidebook; Other: Guidebook and Myofascial Reorganization® (RMF).
    Sponsors: University of the State of Santa Catarina; Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina
    Recruiting

37. Supervised Computerized Active Program for People With Post-COVID Syndrome (SuperCAP Study)

    Thu, 14 Nov 2024 05:00:00 -0000

    Conditions: Post-COVID Condition
    Interventions: Device: SuperCAP Program
    Sponsors: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia; Institut de Recerca de la SIDA IrsiCaixa; Germans Trias i Pujol Hospital
    Recruiting

38. A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

    Fri, 22 Nov 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant; Biological: Novavax COVID-19 Vaccine; Biological: tNIV Vaccine; Biological: Fluzone High Dose
    Sponsors: Novavax
    Not yet recruiting

39. Attention Training for COVID-19 Related Distress

    Tue, 12 Nov 2024 05:00:00 -0000

    Conditions: Anxiety
    Interventions: Behavioral: Attention Bias Modification; Behavioral: Attention Control Training; Behavioral: Neutral training
    Sponsors: Palo Alto University
    Terminated

40. COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk / World Health Organization (WHO)

    Thu, 21 Nov 2024 05:00:00 -0000

    Conditions: Sars-CoV-2 Infection; MIS-C
    Sponsors: Association Clinique Thérapeutique Infantile du val de Marne
    Completed

41. A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

    Thu, 14 Nov 2024 05:00:00 -0000

    Conditions: Influenza; COVID-19
    Interventions: Biological: Influenza and COVID-19 Combination A; Biological: Licensed influenza vaccine; Biological: COVID-19 Vaccine; Biological: Influenza and COVID-19 Combination B; Biological: Placebo; Biological: Investigational influenza vaccine
    Sponsors: BioNTech SE; Pfizer
    Active, not recruiting

42. Connecting Friends and Health Workers to Boost COVID-19 Vaccination in Latino Communities

    Tue, 12 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; Vaccine
    Interventions: Behavioral: REDES; Behavioral: Control
    Sponsors: Johns Hopkins University; National Institute on Minority Health and Health Disparities (NIMHD); Rutgers University
    Recruiting

43. ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

    Wed, 13 Nov 2024 05:00:00 -0000

    Conditions: Covid19
    Interventions: Other: Placebo; Drug: Metformin
    Sponsors: Susanna Naggie, MD; National Center for Advancing Translational Sciences (NCATS); Vanderbilt University Medical Center
    Active, not recruiting

44. Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers

    Fri, 15 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; Vaccines
    Interventions: Biological: AdCLD-CoV19-1 OMI; Biological: Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)
    Sponsors: Cellid Co., Ltd.
    Active, not recruiting

45. Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome

    Mon, 18 Nov 2024 05:00:00 -0000

    Conditions: Post-Acute COVID-19 Syndrome; Fatigue
    Interventions: Other: Dietary intervention to mitigate Post-Acute COVID-19 Syndrome; Other: Attention Control
    Sponsors: University of Maryland, Baltimore
    Recruiting

46. Getting INFORMED and Living Well Among Asian Americans in California

    Fri, 22 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; Well-Being, Psychological
    Interventions: Behavioral: INFORMED-Living Well; Behavioral: Text Messaging Only
    Sponsors: University of California, San Francisco; Chinese Community Health Resource Center; University of California, Davis; University of California, Merced; California Department of Public Health
    Completed

47. RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms

    Mon, 18 Nov 2024 05:00:00 -0000

    Conditions: Long COVID; Long Covid19; Long Covid-19
    Interventions: Other: BrainHQ/Active Comparator Activity; Other: BrainHQ; Other: PASC CoRE; Device: tDCS-active; Device: tDCS-sham
    Sponsors: Duke University
    Active, not recruiting

48. To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID

    Mon, 18 Nov 2024 05:00:00 -0000

    Conditions: Long Covid
    Interventions: Drug: BC 007 or matching placebo
    Sponsors: Berlin Cures GmbH
    Completed

49. ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)

    Fri, 15 Nov 2024 05:00:00 -0000

    Conditions: Covid19
    Interventions: Drug: Fluvoxamine; Other: Placebo
    Sponsors: Susanna Naggie, MD; National Center for Advancing Translational Sciences (NCATS); Vanderbilt University Medical Center
    Completed

50. Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

    Mon, 18 Nov 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: abatacept infusion; Drug: Placebo group
    Sponsors: University of Minnesota
    Recruiting

51. Care for Veterans Post-COVID-19

    Tue, 19 Nov 2024 05:00:00 -0000

    Conditions: Post-Acute COVID-19 Syndrome
    Interventions: Behavioral: Concordant Care Training; Behavioral: Education Packet Training
    Sponsors: VA Office of Research and Development
    Not yet recruiting

52. Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects

    Wed, 13 Nov 2024 05:00:00 -0000

    Conditions: Healthy; COVID-19
    Interventions: Drug: ASC11 tablets; Drug: Placebo; Drug: RTV tablets
    Sponsors: Ascletis Pharmaceuticals Co., Ltd.
    Completed

53. Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study

    Thu, 21 Nov 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Other: ChAdOx1 nCOV-19 vaccine (Vaxzeria); Other: BNT162b2 (Pfizer); Other: Ad26.COV2.S (Janssen); Other: CoronaVac (Sinovac)
    Sponsors: AstraZeneca
    Completed

54. Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease

    Fri, 15 Nov 2024 05:00:00 -0000

    Conditions: Chronic or Recovered Hepatitis B; Chronic or Recovered Hepatitis C; Chronic or Recovered Hepatitis D; NAFLD; NASH
    Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Active, not recruiting

55. eVusheld Assessment reaL wORld Effectiveness at UPMC

    Tue, 12 Nov 2024 05:00:00 -0000

    Conditions: SARS-CoV-2, COVID-19
    Interventions: Drug: EVUSHELD
    Sponsors: AstraZeneca; University of Pittsburgh
    Completed

56. Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

    Wed, 20 Nov 2024 05:00:00 -0000

    Conditions: Viral Lung Infection and Acute Respiratory Failure
    Interventions: Drug: Tozorakimab; Drug: Placebo
    Sponsors: AstraZeneca
    Recruiting

57. Nitrite Supplementation in Long COVID Patients

    Thu, 21 Nov 2024 05:00:00 -0000

    Conditions: Long COVID; Cardiorespiratory Fitness
    Interventions: Dietary Supplement: 210 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK)
    Sponsors: VA Office of Research and Development; University of Pittsburgh
    Recruiting

58. COVID-19 Antibody Responses in Cystic Fibrosis

    Wed, 13 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; Cystic Fibrosis
    Interventions: Biological: Blood sample
    Sponsors: Hospices Civils de Lyon; Queen's University, Belfast
    Active, not recruiting

59. Evaluation of the Relationship of Vitamin D and Vitamin D Binding Protein with Disease Severity in Pediatric Sars-CoV2

    Thu, 21 Nov 2024 05:00:00 -0000

    Conditions: SARS CoV-2 Infection
    Interventions: Diagnostic Test: Vitamin D Binding protein
    Sponsors: Marmara University
    Completed

60. Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)

    Thu, 14 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; Adult; Immunocompromised Patients
    Sponsors: Oliver Cornely, MD; ZKS Köln; German Federal Ministry of Education and Research
    Recruiting

61. A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

    Thu, 21 Nov 2024 05:00:00 -0000

    Conditions: Healthy
    Interventions: Drug: PF-07817883; Drug: Placebo; Drug: Midazolam; Drug: Moxifloxacin
    Sponsors: Pfizer
    Completed

62. PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout

    Tue, 12 Nov 2024 05:00:00 -0000

    Conditions: Depression; Burnout, Professional
    Interventions: Drug: Psilocybin; Behavioral: Mindfulness-Based Stress Reduction (MBSR)
    Sponsors: University of Utah; Heffter Research Institute; Usona Institute
    Completed

63. Effects of Immulina TM Supplements with PASC Patients

    Fri, 15 Nov 2024 05:00:00 -0000

    Conditions: Post Acute COVID-19 Syndrome
    Interventions: Drug: Immulina TM; Dietary Supplement: Placebo
    Sponsors: University of Mississippi Medical Center; National Institute of General Medical Sciences (NIGMS)
    Recruiting

64. MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers

    Wed, 20 Nov 2024 05:00:00 -0000

    Conditions: Post-Traumatic Stress Disorder; Adjustment Disorders
    Interventions: Drug: MDMA
    Sponsors: Willa Hall
    Not yet recruiting

65. Developing an Integrative, Recovery-Based, Post-Acute COVID-19 Syndrome (PACS) Psychotherapeutic Intervention

    Tue, 19 Nov 2024 05:00:00 -0000

    Conditions: Long COVID
    Interventions: Behavioral: Long COVID Coping and Recovery (LCCR) Intervention
    Sponsors: VA Office of Research and Development
    Completed

66. Facilitating COVID-19 Test for Korean Americans Through Korean Schools in Northern California

    Fri, 15 Nov 2024 05:00:00 -0000

    Conditions: Educational Activities
    Interventions: Behavioral: Education; Other: COVID-19 testing kits; Other: Instruction
    Sponsors: University of California, San Francisco; Duke Clinical Research Institute; National Institute on Minority Health and Health Disparities (NIMHD)
    Completed

67. Psychological Well-being and Burnout in Healthcare Workers During the COVID-19 (Coronavirus Disease 2019) Pandemic

    Tue, 19 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; Burnout; Burnout, Professional; Work-related Illness; Work-Related Stress; SARS-CoV-2 Infection
    Interventions: Behavioral: Positive Affect Regulation sKills (PARK)
    Sponsors: Northwestern University
    Completed

68. COVID-19 Experiences in the SELF Cohort

    Tue, 19 Nov 2024 05:00:00 -0000

    Conditions: COVID-19
    Sponsors: National Institute of Environmental Health Sciences (NIEHS)
    Enrolling by invitation

69. The Psychological Impact of COVID-19 on Patients with Solid Malignancies: a Single-Institution Survey Study

    Thu, 14 Nov 2024 05:00:00 -0000

    Conditions: Solid Tumor
    Interventions: Other: Questionnaire
    Sponsors: The Christie NHS Foundation Trust
    Completed

70. Neutralizing Power of Anti-SARS-CoV-2 (Anti-COVID-19) Serum Antibodies

    Tue, 19 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; SARS CoV 2 Infection
    Interventions: Other: Collection of biological samples
    Sponsors: Centre Hospitalier Régional d'Orléans
    Terminated

71. A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.

    Thu, 14 Nov 2024 05:00:00 -0000

    Conditions: Myocarditis
    Interventions: Diagnostic Test: Cardiac Imaging
    Sponsors: Pfizer; Carelon Research; National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

72. EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

    Mon, 18 Nov 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: nirmatrelvir; Drug: ritonavir
    Sponsors: Pfizer
    Recruiting

73. The SINCERE Intervention to Address COVID-19 Health Disparities

    Wed, 20 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; Vulnerable Populations; Social Determinants of Health
    Interventions: Behavioral: SINCERE; Behavioral: Scheduled Follow-Up; Other: Standard of Care
    Sponsors: Andrea Wallace; National Institute of Nursing Research (NINR)
    Recruiting

74. REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19

    Fri, 22 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; Critical Illness; ICU Acquired Weakness; PICS; Cardiorespiratory Fitness
    Interventions: Behavioral: REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT)
    Sponsors: Duke University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Vanderbilt University Medical Center; Ohio State University; University of Kentucky; University of Alabama at Birmingham; Florida Atlantic University
    Recruiting

75. A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults

    Thu, 21 Nov 2024 05:00:00 -0000

    Conditions: Coronavirus Disease 2019 (COVID-19)
    Interventions: Drug: 600 mg AZD7442 IV; Drug: 600mg placebo IV
    Sponsors: AstraZeneca
    Completed

76. A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.

    Fri, 22 Nov 2024 05:00:00 -0000

    Conditions: SARS-CoV-2
    Interventions: Drug: Sodium Chloride; Biological: NDV-HXP-S IN low dose; Biological: NDV-HXP-S IM low dose; Biological: NDV-HXP-S IN high dose; Biological: NDV-HXP-S IM high dose
    Sponsors: Sean Liu
    Active, not recruiting

77. Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

    Wed, 20 Nov 2024 05:00:00 -0000

    Conditions: Papillomavirus Infections; Coronavirus Disease (COVID-19)
    Interventions: Biological: 9vHPV Vaccine; Biological: mRNA-1273 Vaccine
    Sponsors: Merck Sharp & Dohme LLC
    Completed

78. ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome

    Fri, 22 Nov 2024 05:00:00 -0000

    Conditions: Covid19; Postviral Syndrome; Dyspnea
    Interventions: Biological: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles; Other: Saline
    Sponsors: Direct Biologics, LLC
    Withdrawn

79. Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

    Tue, 19 Nov 2024 05:00:00 -0000

    Conditions: Dysexecutive Syndrome; Post-Acute Sequelae of COVID-19
    Interventions: Device: Active tDCS; Device: Sham tDCS
    Sponsors: Massachusetts General Hospital
    Recruiting

80. Cromolyn Sodium for Treatment of COVID-19 Pneumonia

    Mon, 18 Nov 2024 05:00:00 -0000

    Conditions: COVID-19 Pneumonia; COVID-19 Respiratory Infection; Pneumonia, Viral
    Interventions: Drug: Cromolyn Sodium; Other: Placebo
    Sponsors: Texas Tech University Health Sciences Center, El Paso
    Terminated

81. Covid-19 Predictors: Safety of Gynecological Oncology Patients Undergoing Systemic Cancer Therapy

    Fri, 22 Nov 2024 05:00:00 -0000

    Conditions: Telemedicine
    Interventions: Device: PPG and PROM
    Sponsors: Technical University of Munich
    Active, not recruiting

82. Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

    Fri, 22 Nov 2024 05:00:00 -0000

    Conditions: Covid19
    Interventions: Drug: AntiCov-220 (1); Drug: AntiCov-220 (2)
    Sponsors: Nguyen Thi Trieu, MD
    Completed

83. Telehealth 2.0: Evaluating Effectiveness and Engagement Strategies for CPT-Text for PTSD

    Fri, 22 Nov 2024 05:00:00 -0000

    Conditions: Posttraumatic Stress Disorder
    Interventions: Behavioral: CPT-Text; Behavioral: Culturally Informed Trauma Treatment (CITT); Behavioral: Retention Incentive; Behavioral: Reminder as Usual
    Sponsors: Stanford University; The University of Texas Health Science Center at San Antonio; Talkspace; National Institute of Mental Health (NIMH); University of Pennsylvania
    Recruiting

84. Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

    Fri, 22 Nov 2024 05:00:00 -0000

    Conditions: SARS-CoV-2 Infection; COVID-19; SARS-CoV-2 Acute Respiratory Disease; SARS (Disease)
    Interventions: Biological: BNT162b2; Biological: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2); Biological: Monovalent BNT162b2 (B.1.1.7); Biological: Monovalent BNT162b2 (B.1.617.2); Biological: Monovalent BNT162b2 (B.1.1.529.1); Other: Observational
    Sponsors: BioNTech SE
    Completed

85. ACTIV-6: COVID-19 Study of Repurposed Medications

    Wed, 13 Nov 2024 05:00:00 -0000

    Conditions: Covid19
    Interventions: Drug: Ivermectin; Drug: Fluvoxamine; Drug: Fluticasone; Other: Placebo; Drug: Montelukast; Drug: Metformin
    Sponsors: Susanna Naggie, MD; National Center for Advancing Translational Sciences (NCATS); Vanderbilt University Medical Center
    Completed

86. Myocardial Injury and Quality of Life After COVID-19

    Tue, 19 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; Myocardial Injury; Myocarditis Post Infection
    Sponsors: Voronezh Regional Clinical Consultative and Diagnostic Center; Voronezh State Medical University named after N.N. Burdenko; Charles University, Czech Republic
    Completed

87. A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)

    Wed, 13 Nov 2024 05:00:00 -0000

    Conditions: COVID-19 Prevention
    Interventions: Biological: Ad26.COV2.S
    Sponsors: Janssen Vaccines & Prevention B.V.
    Completed

88. AGILE (Early Phase Platform Trial for COVID-19)

    Tue, 19 Nov 2024 05:00:00 -0000

    Conditions: Covid19
    Interventions: Drug: CST-2: EIDD-2801; Drug: CST-2: Placebo; Drug: Nitazoxanide; Drug: VIR-7832; Drug: VIR-7831; Drug: CST-5: Placebo; Drug: Favipiravir; Drug: Molnupiravir; Drug: Paxlovid; Drug: ALG-097558; Drug: ALG-097558 and Remdesivir; Drug: NHS standard of care as per COVID-19 treatment guidelines
    Sponsors: University of Liverpool; Liverpool School of Tropical Medicine; Royal Liverpool University Hospital; University of Cambridge
    Active, not recruiting

89. COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults

    Fri, 15 Nov 2024 05:00:00 -0000

    Conditions: Covid19
    Interventions: Biological: hAd5-S-Fusion+N-ETSD vaccine
    Sponsors: ImmunityBio, Inc.
    Completed

90. Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases

    Tue, 19 Nov 2024 05:00:00 -0000

    Conditions: Systemic Autoimmune Diseases
    Sponsors: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Recruiting

91. Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS

    Fri, 22 Nov 2024 05:00:00 -0000

    Conditions: Covid19; ARDS; Hypoxia; Cytokine Storm
    Interventions: Biological: ExoFlo
    Sponsors: Direct Biologics, LLC
    No longer available

92. The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19

    Wed, 13 Nov 2024 05:00:00 -0000

    Conditions: This is a Pilot Study Which Aims to Assess the Validity and Applicability of Lateral Flow Assays (LFAs) Which Can be Used as a Point of Care Test for COVID-19; Covid19
    Interventions: Device: Innova Lateral Flow Device
    Sponsors: Alder Hey Children's NHS Foundation Trust
    Completed

93. Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic

    Thu, 21 Nov 2024 05:00:00 -0000

    Conditions: Distress, Emotional; Emotional Dysfunction; Anxiety; Depression
    Interventions: Behavioral: Emotion Regulation Training via Telehealth
    Sponsors: Teachers College, Columbia University; University of Michigan
    Completed

94. COVID-19 on Placental Gene Expression and Pathology

    Mon, 18 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; SARS-CoV-2 Infection
    Interventions: Diagnostic Test: Positive for SARS-CoV-2 infection
    Sponsors: Prisma Health-Upstate
    Completed

95. Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic

    Wed, 13 Nov 2024 05:00:00 -0000

    Conditions: COVID-19 Infection; Melanoma
    Interventions: Other: Survey Administration
    Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
    Recruiting

96. Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19

    Tue, 12 Nov 2024 05:00:00 -0000

    Conditions: Severe Acute Respiratory Syndrome
    Interventions: Drug: Camostat Mesilate; Other: Standard of Care
    Sponsors: Alan Bryce
    Completed

97. Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19

    Fri, 15 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; Critical Illness
    Interventions: Other: Admission to ICU for COVID-19
    Sponsors: Linkoeping University; Region Östergötland
    Active, not recruiting

98. Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection

    Mon, 18 Nov 2024 05:00:00 -0000

    Conditions: COVID-19 Infection
    Interventions: Procedure: Convalescent Plasma
    Sponsors: National and Kapodistrian University of Athens; Hellenic Society of Hematology
    Completed

99. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19

    Thu, 14 Nov 2024 05:00:00 -0000

    Conditions: COVID-19; ARDS
    Interventions: Biological: SOC plus 15mg/kg EB05 IV; Other: SOC plus Placebo IV
    Sponsors: Edesa Biotech Inc.; JSS Medical Research Inc.
    Suspended

100. COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study

     Tue, 12 Nov 2024 05:00:00 -0000

     Conditions: Alcohol Drinking; Alcohol-Related Disorders; Pandemic; Psychological Stress
     Sponsors: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
     Recruiting

101. NCI COVID-19 in Cancer Patients, NCCAPS Study

     Tue, 12 Nov 2024 05:00:00 -0000

     Conditions: COVID-19 Infection; Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm
     Interventions: Procedure: Biospecimen Collection; Other: Data Collection; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
     Sponsors: National Cancer Institute (NCI)
     Active, not recruiting

102. A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)

     Wed, 13 Nov 2024 05:00:00 -0000

     Conditions: COVID-19
     Interventions: Drug: IMU-838; Other: Placebo
     Sponsors: Immunic AG; FGK Clinical Research GmbH
     Completed

103. Breath Analysis Based Disease Biomarkers

     Fri, 15 Nov 2024 05:00:00 -0000

     Conditions: Liver Diseases; Liver Cancer; COVID19
     Interventions: Diagnostic Test: Collection of breath sample
     Sponsors: Mayo Clinic
     Completed

104. Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy

     Wed, 13 Nov 2024 05:00:00 -0000

     Conditions: SARS-CoV-2
     Sponsors: Insel Gruppe AG, University Hospital Bern
     Completed

105. Impact of the Coronavirus (COVID-19) on Patients With Cancer

     Fri, 22 Nov 2024 05:00:00 -0000

     Conditions: Cancer; COVID-19
     Sponsors: Stanford University
     Recruiting

106. Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients with Breast Cancer Undergoing Breast Surgery

     Thu, 21 Nov 2024 05:00:00 -0000

     Conditions: Breast Ductal Carcinoma in Situ; COVID-19 Infection; Hereditary Breast Carcinoma; Invasive Breast Carcinoma
     Interventions: Other: Questionnaire Administration
     Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
     Recruiting

107. Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)

     Wed, 13 Nov 2024 05:00:00 -0000

     Conditions: ARDS
     Interventions: Other: Respiratory Mechanics; Other: Standard Ventilation Strategy
     Sponsors: Unity Health Toronto; Canadian Institutes of Health Research (CIHR); University of Toronto; Applied Health Research Centre
     Recruiting

108. Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

     Wed, 20 Nov 2024 05:00:00 -0000

     Conditions: Lower Respiratory Tract Infection; Parainfluenza; Immunocompromised; COVID-19
     Interventions: Drug: DAS181; Drug: Placebo; Drug: DAS181 COVID-19; Drug: DAS181 OL
     Sponsors: Ansun Biopharma, Inc.
     Recruiting

109. Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

     Tue, 12 Nov 2024 05:00:00 -0000

     Conditions: Sickle Cell Disease (SCD)
     Interventions: Drug: Crizanlizumab
     Sponsors: Novartis Pharmaceuticals
     Active, not recruiting

110. Viral Infections in Healthy and Immunocompromised Hosts

     Wed, 20 Nov 2024 05:00:00 -0000

     Conditions: Anogenital Herpes; COVID-19; Herpes Labialis
     Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
     Recruiting